Acadia, page-304

Sillazze posted the following yesterday:
"I conclude by saying that behind these attacks there is the hand of someone who has hostile interests in the acquisition of Neuren with full knowledge that each update on 2591 will correspond to a higher level of discount rate of the NEU stock.Having taken note of the dynamics and timing of these two attacks, I believe there is no longer any doubt that the practitioner is Acadia, with his 2 million shares to manipulate and destabilize the price of NEU as much as possible."
If the above is accurate:
*Does any one else have concerns about the Neuren commercial relationship with Acadia[Baker Bros] and is it worth the paper it is written on.
*Concerns that the so-called jewel in the Neuren crown has been licenced to Acadia for Retts and Fragile X and patented data could be copied.Acadia have already paid to have a good look at NNZ-2591 and how it works.
*If Baker Bros wanted to sell Acadia would it be more favourable or not for them to have Neuren not taken out by another pharma.Acadia management appear to be mainly interested in earnings per share numbers but the company still never turns a profit.
Kens.